Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00373594 |
| Other study ID # |
911238 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 2
|
| First received |
September 7, 2006 |
| Last updated |
June 18, 2010 |
| Start date |
June 2005 |
| Est. completion date |
May 2010 |
Study information
| Verified date |
June 2010 |
| Source |
University of Bergen |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Norway: Norwegian Medicines Agency |
| Study type |
Interventional
|
Clinical Trial Summary
Chronic cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (anemia due
to destruction of red blood cells by abnormal antibodies). Almost all patients also suffer
from cold-induced disturbances of blood circulation. The purpose of this study is to assess
the efficacy and safety of combination therapy with rituximab (an antibody against B
lymphocytes) and fludarabine (a cytotoxic drug) for CAD. Another aim is to try to assess
whether these agents in combination are better than single agent therapy with rituximab.
Description:
1. Background
Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies
that bind to erythrocyte surface antigens, causing haemagglutination and complement-mediated
haemolysis. Anaemia is severe (Hb 8.0 g/dL or lower) in one-third of patients and
complement-induced exacerbation during febrile illness occurs frequently 1-3. Cold-induced
circulatory symptoms are present in more than 90% of patients and may be disabling 1. CAD
not associated with overt lymphoma or other disease has traditionally been classified as
primary or idiopathic. However, a lymphoproliferative bone marrow disorder can be
demonstrated by flow cytometry in 90% and by histology in approximately 75% of these
patients, characterized by clonal proliferation of CD20+,κ+ B-cells 1,4,5. The histological
features are those of lymphoplasmacytic lymphoma in about 50% of the patients 1.
Many standard therapies used in other autoimmune diseases or indolent lymphomas are
inefficient, e.g. corticosteroids, alkylating agents, interferon-α and, probably, purine
analogue single agent therapy 1,6-8. Treatment with the chimeric monoclonal anti-CD20
antibody rituximab has been shown in prospective studies to induce remission in more than
half of patients 9,10. Almost all responses were partial, however, and the median response
duration was less than one year. Further studies are warranted, therefore, in order to
explore the possibilities for increasing the response rate and duration.
The purine analogues, cladribine and fludarabine, are not cyclus dependent, and they have
yielded partial response rates of 30-75% and complete response rates of 3-10% in
lymphoplasmacytic lymphoma 11,12. Although probably clinically inefficient as monotherapy in
most CAD patients, clinical effect of fludarabine has been reported in a single case 13, and
cladribine has been shown to induce tumour reduction even in this condition 8. In
lymphoplasmacytic lymphoma, purine analogue and rituximab combination therapy has resulted
in higher response rates and more prolonged remissions as compared to purine analogue single
agent therapy 12. The combination has produced favourable results in some patients with the
related condition cryoglobulinaemia type I 14. Fludarabine has induced autoimmune haemolytic
anaemia in patients with chronic lymphocytic leukaemia, but such events have not been
reported in CAD patients 13,15. Moreover, there are reasons to assume that rituximab therapy
will further reduce the risk of this adverse effect of fludarabine 16.
2 Clinical study
The clinical study is a prospective, non-randomized multicentre study in order to
investigate the efficacy and safety of rituximab and fludarabine combination therapy in
patients with CAD. The protocol has approved by the Regional Medical Research Ethics
Committee of Southern Norway, Norwegian Medicines Agency (EudraCT nr: 2004-002936-25), and
Norwegian Social Science Data Services (Privacy Issue Unit).
2.1 Study objectives
The major study objective is to assess efficacy of rituximab and fludarabine in combination
for patients with CAD.
The second objective is to assess safety of rituximab and fludarabine in combination for
patients with CAD.
The third objective is to try to assess whether rituximab and fludarabine in combination are
superior to rituximab monotherapy comparing patients who have received both therapies for
CAD.
2.2 Study design
A prospective, non-randomized international multicentre study.
Registration
Treatment:
Day 1: Rituximab; 375 mg/m2 Day 1-5: Fludarabine orally; 40 mg/m2
Day 28: Rituximab; 375 mg/m2 Day 28-33: Fludarabine orally; 40 mg/m2
Day 56: Rituximab; 375 mg/m2 Day 56-60: Fludarabine orally; 40 mg/m2
Day 84: Rituximab; 375 mg/m2 Day 84-88: Fludarabine orally; 40 mg/m2
Evaluation
2.3 Dose adjustments
Doses of fludarabine will be adjusted in case of haematological toxicity or renal
insufficiency. For details, see chapter 4.3.
2.4 Study population
2.4.1 Inclusion criteria
1. CAD diagnosis defined by the combination of -
1. Chronic haemolysis
2. Cold agglutinin titre > 64
3. Positive direct antiglobulin test when performed with polyspecific antiserum,
negative (or only weakly positive) with anti-IgG, and strongly positive with
anti-C3d
2. The presence of a clonal B-cell lymphoproliferative disorder defined by -
1. Monoclonal IgMκ band by serum electrophoresis and immunofixation, and
2. Lymphocyte phenotype with κ/λ-ratio > 3.5 and CD20+,κ+ co-expression, using
flowcytometric immunophenotyping of bone marrow aspirates
3. Clinical symptoms requiring treatment, such as anaemia or Raynaud-like symptoms
4. Informed consent
2.4.2 Exclusion criteria
1. An aggressive lymphoma
2. Blood lymphocyte count > 50 . 109/L
3. Non-lymphatic malignant disease other than basal cell carcinoma
4. Contra-indications to rituximab or fludarabine therapy
5. Inability to cooperate
2.5. Response criteria
Responses will be assessed using the following, previously published definitions 8,9,17:
Complete response (CR), Absence of anemia, no signs of hemolysis, no clinical symptoms of
CAD, undetectable serum monoclonal protein, and no signs of clonal lymphoproliferation by
bone marrow histology, immunohistochemistry and flow cytometry.
Partial response (PR), Stable increase in Hb levels by at least 2.0 g/dL or to the normal
range, combined with a reduction of serum IgM concentrations by at least 50% or to the
normal range, improvement of clinical symptoms, and transfusion independency.
Non-response (NR), Patients not meeting the criteria for CR or PR.
3 Patient examination at inclusion
3.1 History. Clinical and radiological examination
Year of first occurrence of clinical symptoms is registered along with data on haemolytic
anaemia, circulatory symptoms, cold- or fever-induced exacerbation, previous therapies,
lymph node enlargement, and spleen size (clinical assessment). Chest radiograph and
abdominal ultrasonography should be done if not performed already during the last four
months.
3.2 Blood tests
Haemolysis is detected and quantified based on Hb, reticulocyte count (x 109/L), LDH,
bilirubin and haptoglobin. These measurements should be done twice during the last two
months before treatment.
The following haematological, biochemical and immunological assessments should be done once
at inclusion:
- WBC, leukocyte differential count, platelet count
- Iron, transferrin (or TIBC), ferritin, cobalamine and folate
- CRP
- Quantification of IgM, IgG and IgA
- Serum electrophoreses with immunofixation (*) (Immunofixation must be performed even if
visual assessment of agarose electrophoreses does not show any monoclonal band.)
- Cold agglutinin titre (*)
- Specific direct antiglobulin test (DAT, direct Coombs' test), i.e. using polyspecific
antiserum, anti-C3d and anti-IgG)
- Complement assessments (C3, C4 and CH50) (*, **)
- CMV and VZV antibodies
- Freezing of 5 ml serum (*, **)
- Freezing of 5 ml EDTA-blood for possible later DNA-based studies (**)
Remarks:See protocol text.
3.3 Bone marrow examinations
Centres outside Norway should follow the guidelines listed below. Norwegian centres should
refer to the Norwegian protocol version.
I.) Morphologic assessment of bone marrow aspirate is performed according to the routines of
the participating centre.
II.) A bone marrow trephine biopsy should be obtained according to the routines of the
department. Morphological and immunohistochemical assessments are to be done at a university
pathology laboratory by an experienced haematopathologist. If possible, a fresh biopsy
specimen should be preferred.
III.) Flow-cytometric immunophenotyping of bone marrow aspirate should be done at a
university hospital laboratory. Cells should be washed at 37oC in order to remove cold
agglutinins, using the previously published procedure 5 (Appendix 1) or an equally
satisfactory method. The antibody panel should comprise CD19, CD20, CD5, kappa, lambda and
preferably also IgM and IgG. The kappa/lambda ratio should be calculated. CD20 expression is
registered semi-quantitatively as 0, + or ++.
IV.) If possible, 5 ml bone marrow aspirate should be frozen at -70oC for the purpose of
later DNA-based examinations.
4 Therapy
4.1 Treatment schedule
Day 1: Rituximab; 375 mg/m2 Day 1-5: Fludarabine orally; 40 mg/m2
Day 28: Rituximab; 375 mg/m2 Day 28-33: Fludarabine orally; 40 mg/m2
Day 56: Rituximab; 375 mg/m2 Day 56-60: Fludarabine orally; 40 mg/m2
Day 84: Rituximab; 375 mg/m2 Day 84-88: Fludarabine orally; 40 mg/m2
4.2 Administration and precautions
Administration and monitoring of rituximab and fludarabine therapy should be in accordance
with the manufacturers' recommendations, the official regulations that apply in the
participating country, and the routine procedures of the participating unit.
4.3 Dose adjustments
4.3.1 Haematological toxicity If ANC<1,0x109/L and/or platelets<75x109/L at day 1 of any
cycle treatment should be delayed for up to 2 weeks and fludarabine dose should be reduced
to 30 mg/m2 in the remaining cycles. Myelosuppression of the same degree in the subsequent
cycles should result in a reduction of the fludarabine dose to 20 mg/m2.
Adjustments of the rituximab dose should not be done due to myelosuppression.
4.3.2 Renal insufficiency In patients with a creatinine clearance between 30-60 ml/min the
fludarabine dose should be reduced to 20 mg/m2. Patients with a creatinine clearance below
30 ml/min are not eligible for the study.
5 Evaluation
5.1 Follow-up during treatment
The parameters listed below must be recorded before each therapy cycle:
Clinical condition, possible adverse effects, need for transfusion, Hb, reticulocytes count,
WBC including differential count, platelet count, CRP, LDH, ASAT, ALAT, alkaline
phosphatase, urea, creatinine, bilirubin and haptoglobin.
Any adverse effects of fludarabine are registered in CRF 2 (Appendix 3). Any adverse effects
of rituximab are registered in CRF 3 (Appendix 4). In case of death or other serious events,
these should be reported without delay to S. Berentsen or G. Tjønnfjord as well as the
relevant national authorities according to regulations that apply in the participating
country.
5.2 Follow-up after treatment (first six months)
A.) The following measurements must be done monthly during the first six months after the
last cycle of therapy:
I.) All measurements listed in Paragraph 5.1. II.) Quantification of immunoglobulin classes.
In case of reduction of a previously elevated IgM level to the normal range, serum
electrophoresis with immunofixation should be performed at the next visit.
III.) Number of blood transfusions after the previous registration.
B.) At the first visit after cessation of therapy, a new bone marrow biopsy is performed in
those patients where histological or immunohistochemical signs of a lymphoproliferative
disorder were present at baseline. If a lymphoproliferative bone marrow involvement could be
detected at baseline by flow cytometry only, flow-cytometric immunophenotyping is also
repeated at this visit.
C.) Bone marrow examinations should also be repeated four months after the last therapy
cycle if the examinations three months before showed signs of lymphoma.
5.3 Long-term follow-up
When more than six months have passed since cessation of treatment, patients should be
followed every third month for three years or until they need treatment again.
